136 related articles for article (PubMed ID: 36001203)
1. Safety of temozolomide use in adult patients with renal dysfunction.
Garzio K; McElroy K; Grossman S; Holdhoff M; Ozer B; Yankulina O
J Neurooncol; 2022 Sep; 159(3):591-596. PubMed ID: 36001203
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Gupta T; Mohanty S; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
[TBL] [Abstract][Full Text] [Related]
3. Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
O'Leary B; Mandeville HC; Fersht N; Solda F; Mycroft J; Zacharoulis S; Vaidya S; Saran F
J Neurooncol; 2016 Apr; 127(2):295-302. PubMed ID: 26842817
[TBL] [Abstract][Full Text] [Related]
4. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Gerber DE; Grossman SA; Zeltzman M; Parisi MA; Kleinberg L
Neuro Oncol; 2007 Jan; 9(1):47-52. PubMed ID: 17108062
[TBL] [Abstract][Full Text] [Related]
5. The safety of temozolomide in the treatment of malignancies.
Trinh VA; Patel SP; Hwu WJ
Expert Opin Drug Saf; 2009 Jul; 8(4):493-9. PubMed ID: 19435405
[TBL] [Abstract][Full Text] [Related]
6. Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Ishikawa E; Yamamoto T; Sakamoto N; Nakai K; Akutsu H; Tsuboi K; Takano S; Matsumura A
Neurol Med Chir (Tokyo); 2010; 50(8):638-44. PubMed ID: 20805645
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Lee EQ; Puduvalli VK; Reid JM; Kuhn JG; Lamborn KR; Cloughesy TF; Chang SM; Drappatz J; Yung WK; Gilbert MR; Robins HI; Lieberman FS; Lassman AB; McGovern RM; Xu J; Desideri S; Ye X; Ames MM; Espinoza-Delgado I; Prados MD; Wen PY
Clin Cancer Res; 2012 Nov; 18(21):6032-9. PubMed ID: 22923449
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Ridola V; Barone G; Lazzareschi I; Ruggiero A; Rizzo D; Riccardi R
J Neurooncol; 2011 May; 103(1):147-53. PubMed ID: 20811928
[TBL] [Abstract][Full Text] [Related]
11. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Su YB; Sohn S; Krown SE; Livingston PO; Wolchok JD; Quinn C; Williams L; Foster T; Sepkowitz KA; Chapman PB
J Clin Oncol; 2004 Feb; 22(4):610-6. PubMed ID: 14726505
[TBL] [Abstract][Full Text] [Related]
12. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
14. Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Zwinkels H; Roon K; Jeurissen FJ; Taphoorn MJ; Hop WC; Vecht CJ
Oncol Nurs Forum; 2009 Mar; 36(2):225-31. PubMed ID: 19273412
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Newlands ES; Foster T; Zaknoen S
Br J Cancer; 2003 Jul; 89(2):248-51. PubMed ID: 12865911
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Chamberlain MC
Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
[TBL] [Abstract][Full Text] [Related]
18. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.
Chiesa S; Hohaus S; Falcinelli L; D'Alò F; Martelli MF; Manfrida S; Beghella Bartoli F; Colosimo C; Valentini V; Aristei C; Balducci M
Ann Hematol; 2020 Oct; 99(10):2367-2375. PubMed ID: 32816079
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Riccardi A; Mazzarella G; Cefalo G; Garrè ML; Massimino M; Barone C; Sandri A; Ridola V; Ruggiero A; Mastrangelo S; Lazzareschi I; Caldarelli M; Maira G; Madon E; Riccardi R
Cancer Chemother Pharmacol; 2003 Dec; 52(6):459-64. PubMed ID: 13680160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
